Welcome to our dedicated page for Adicet Bio SEC filings (Ticker: ACET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adicet Bio, Inc. filings document the regulatory record of a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies. Its Form 8-K reports cover material events, financial results, clinical and regulatory updates for prula-cel and ADI-212, Nasdaq listing-rule matters, and capital-structure disclosures involving common stock and pre-funded warrants.
Proxy filings describe shareholder voting matters, board and governance procedures, executive compensation, equity-award disclosures, and proposals affecting the company’s certificate of incorporation and share structure. These documents connect Adicet’s cell-therapy pipeline with its public-company governance, equity compensation, and financing-related disclosure obligations.
Adicet Bio, Inc.’s Chief Technology Officer Don Healey reported an administrative share adjustment related to equity compensation. On 01/24/2026, 535 shares of common stock were withheld by the company at $8.44 per share to cover tax obligations from vesting restricted stock units, rather than being sold on the market. Following this transaction, Healey beneficially owns 3,452 shares of Adicet Bio common stock on a direct basis. The reported holdings also reflect a previously effected 1-for-16 reverse stock split completed on December 30, 2025, which adjusted the share counts.
Adicet Bio President & CEO Schor Chen reported a routine share withholding related to equity compensation. On January 24, 2026, the company withheld 1,755 shares of common stock at $8.44 per share to cover tax obligations from vesting restricted stock units, which is not a market sale.
After this transaction, Chen reports 6,820 common shares held directly. In addition, 2,716 shares are held indirectly through The I. Schor IRRV Trust and 3,339 shares are held indirectly through The C. Schor IRRV Trust, both irrevocable family trusts with independent trustees. The holdings reflect a previously effected 1-for-16 reverse stock split.
Adicet Bio Chief Financial Officer Brian Nicholas Harvey reported a routine tax withholding related to restricted stock units. On January 24, 2026, 546 shares of Adicet Bio common stock were withheld at $8.44 per share to cover tax obligations upon RSU vesting, and this did not involve an open-market sale. After this withholding and giving effect to a 1-for-16 reverse stock split completed on December 30, 2025, he beneficially owned 5,145 common shares directly.
Adicet Bio reported clinical and regulatory progress for its cell therapy programs. Enrollment in its Phase 1 trial of prulacabtagene leucel (prula-cel, formerly ADI-001) in autoimmune diseases has doubled to over 20 patients as of December 31, 2025. The company has also reached alignment with the U.S. Food and Drug Administration to allow patients with lupus nephritis and systemic lupus erythematosus to be dosed with prula-cel in the outpatient setting in ongoing and future trials. Adicet plans to request a meeting with the FDA in the second quarter of 2026 to inform potential Phase 2 pivotal trial design for prula-cel and expects to submit a regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer in the first half of 2026.
Adicet Bio, Inc. (ACET) has called a virtual special meeting of stockholders on December 19, 2025 to vote on a reverse stock split and a possible adjournment of the meeting. The company is asking investors to approve an amendment to its certificate of incorporation that would allow the board to combine existing common shares into a smaller number of shares at a ratio between one-for-five and one-for-thirty, with the exact ratio set later by the board. As of November 14, 2025, Adicet Bio had 153,255,581 common shares outstanding and its stock closed at $0.66 per share, below Nasdaq’s $1.00 minimum bid requirement. The board explains that the reverse split is intended to help regain compliance with Nasdaq listing rules and potentially broaden investor interest. A second proposal would allow the meeting to be adjourned to solicit additional proxies if there are not enough votes to approve the reverse split.
Adicet Bio (ACET) called a virtual special meeting to seek stockholder approval to amend its charter to effect a reverse stock split within a range of one-for-five to one-for-thirty, with the exact ratio set by the board in its sole discretion. The company says the split is intended to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement; its closing bid was $0.6903 on November 4, 2025.
The meeting is scheduled for December 19, 2025 at 8:00 a.m. ET, and will be held online at www.virtualshareholdermeeting.com/ACET2025SM. Only holders of record as of November 14, 2025 may vote. A separate proposal would allow adjournment to solicit additional proxies if needed.
If implemented, fractional shares will be paid in cash, outstanding share counts will be reduced by the chosen ratio, and authorized shares will remain at 300,000,000, increasing the proportion of authorized but unissued shares. The board may implement the split within one year of approval or abandon it at its discretion.
Adicet Bio (ACET) reported Q3 2025 results with a net loss of $26,856,000 and total operating expenses of $27,952,000 (research and development $22,853,000; general and administrative $5,099,000). Interest income was $1,172,000.
Liquidity remained the key focus. As of September 30, 2025, cash and cash equivalents were $29,099,000 and short‑term U.S. treasury investments were $73,999,000. Net cash used in operating activities for the nine months was $74,337,000. Management states current cash, cash equivalents and short‑term treasuries are expected to fund operations for at least twelve months from issuance.
In October 2025, the company completed an underwritten registered direct offering of 70,001,000 shares at $1.00 and pre‑funded warrants to purchase 10,000,000 shares at $0.9999, generating net proceeds of approximately $74,800,000. ACET transferred its listing to the Nasdaq Capital Market on October 9, 2025 for an additional compliance period under the minimum bid price rule. Shares outstanding were 153,255,581 as of November 3, 2025.
Adicet Bio (ACET) filed an 8-K stating it announced financial results for the quarter ended September 30, 2025.
The detailed results are provided in a press release furnished as Exhibit 99.1. The company specifies that the information in this report and Exhibit 99.1 is being furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities, nor incorporated by reference except as specifically stated.
OrbiMed-related entities reported purchases of Adicet Bio (ACET) common stock on 10/08/2025. The filings show two registered direct offering purchases: 1,500,000 shares at $1 and 3,500,000 shares at $1, increasing combined holdings across affiliated OrbiMed funds and GP vehicles to 9,026,359 and 4,490,254 shares in specific accounts, with additional holdings noted across other funds. The report lists multiple OrbiMed entities and explains their record ownership and GP relationships, while each entity disclaims direct beneficial ownership except to the extent of pecuniary interest. The Form 4s are signed by Carl L. Gordon on 10/10/2025.
OrbiMed filed Amendment No. 8 to its Schedule 13D reporting its holdings in Adicet Bio, Inc. following an underwritten registered direct offering completed on 10/08/2025. The offering issued 70,001,000 new Shares at $1.00 each and raised the issuer's total outstanding Shares to 153,253,530, which reduced the Reporting Persons' ownership percentage.
Collectively, the Reporting Persons may be deemed to beneficially own 14,772,598 Shares, representing 9.6% of the outstanding class. Two affiliated limited partnerships participated directly in the offering: OPI V purchased 1,500,000 Shares and OPI VI purchased 3,500,000 Shares, each at $1.00 per Share. The filing reiterates that OrbiMed acts as manager/general partner to several funds that hold these positions and preserves discretion to buy or sell in the future.